Beylerli, Ozal,
Gareev, Ilgiz,
Musaev, Elmar,
Roumiantsev, Sergey,
Chekhonin, Vladimir,
Ahmad, Aamir,
Chao, Yuan,
Yang, Guang (2025) -tumor barrier (BTB), which limit the efficacy of systemic
therapies. Recent advances in molecular biology
of the potential of immune system-derived miRNAs to revolutionize CVD management and
therapy, addressing a major
the potential of stromal vascular fraction (SVF) cell
therapy as a novel regenerative treatment for ICH. SVF
Sangeet, Ghai,,
Ni, Tiffany T.,
Pavlovich, Christian P.,
Futterer, Jurgen J.,
Schade, George R.,
Sanchez-Salas, Rafael,
Cornud, Francois,
Eggener, Scott,
Feller, John F.,
George, Arvin K.,
Villers, Arnauld,
de la Rosette, Jean (2025) -related morbidities associated with conventional
therapies. Focal
therapy (FT) is emerging as a promising alternative
Liu, Kang,
Wong, Chris Ho-Ming,
Zhao, Hongda,
Ng, Chi Fai,
Teoh, Jeremy Yuen-Chun,
Laguna, Pilar (2025) who discontinued AA use in comparison to those who continued AA
therapy. Univariable and multivariable